Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
about
Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome.Pharmacological properties of the central antihypertensive agent, moxonidine.Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.Central Sympathetic Modulation Reverses Microvascular Alterations in a Rat Model of High-Fat Diet-Induced Metabolic Syndrome.
P2860
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@en
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@nl
type
label
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@en
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@nl
prefLabel
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@en
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@nl
P2093
P2860
P1476
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
@en
P2093
Rachel Kossover
Rodney A Velliquette
Stephen F Previs
P2860
P2888
P304
P356
10.1007/S00210-005-0024-3
P577
2006-01-17T00:00:00Z